Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ARIMIDEX
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
- ETHAN - ET for Male BC
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
- SMMART Adaptive Clinical Treatment (ACT) Trial
- Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
- Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers
- Onapristone and Anastrozole in Refractory Estrogen and Progesterone Positive Endometrial Cancer
- Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
- Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
- Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fed Condition
- Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fasted Condition
- Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
- Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
- Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
- FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer
- Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
- Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
- Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
- T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Locoregionally Recurrent HER2- Negative Breast Cancer
- Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer
- Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
- Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
- Pulmonary Hypertension and Anastrozole Trial
- Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
- FASN Inhibitor TVB-2640 and Trastuzumab in Combination With Paclitaxel or Endocrine Therapy for the Treatment of HER2 Positive Metastatic Breast Cancer
- Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
- Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
- Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
- Cardiovascular Outcomes of Low Testosterone
- Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)
- A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
- NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
- Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
- Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
- Phase II Study of Everolimus Beyond Progression
- Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial
- Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC
- S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
- Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
- GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
- Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
- Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
- Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients
- Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients
- A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
- Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
- Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
- Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading
- Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
- A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
- Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
- Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects
- Anastrozole in Patients With Pulmonary Arterial Hypertension
- Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
- Study of Arimidex and Radiotherapy Sequencing
- Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
- Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
- Adjuvant AI Combined With Zoladex
- MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
- Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
- ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
- Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
- Anastrozole 1 mg Tablets Under Fed Conditions
- Anastrozole 1 mg Tablets Under Fasting Conditions
- Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fed Conditions
- Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting Conditions
- Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
- Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
- Bioequivalence Study of Anastrozole 1 mg Tablet
- Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain
- Pre-Surgical Intervention for Targeted Therapies for Breast Cancer
- Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
- Arimidex Therapy Compliance Electronic Monitoring System
- Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
- STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing)
- ATAC - Arimidex, Tamoxifen Alone or in Combination
- ATAC - Endometrial Sub-Protocol
- ATAC - Bone Density Sub-Protocol
- ATAC - Pharmacokinetics (PK) Sub-Protocol
- ATAC - Quality of Life Sub-Protocol
- Regulation of Cortisol Metabolism and Fat Patterning
- Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy
- Breast Cancer Tumor Care Observational Programme
- Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
- Gynecomastia Extension Study
- Second Line Breast Cancer Trial
- Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics
- Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
- Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer
- Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
- Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer
- Patient's Anastrozole Compliance to Therapy Programme
- Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure
- Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole
- Liver Safety Under Upfront Arimidex vs Tamoxifen
- PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer
- Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects
- Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
- Aromatase Inhibitors in the Treatment of Male Infertility
- Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome
- Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer
- Insulin Sensitivity in Men With the Metabolic Syndrome
- Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
- Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer
- Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
- Faslodex Advanced Breast Cancer Local Chinese Study
- Arthralgia During Anastrozole Therapy for Breast Cancer
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
- Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer
- Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer
- Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
- Secondary Adjuvant Long Term Study With Arimidex
- ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
- Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
- Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis
- ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
- A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
- Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
- Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
- Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
- Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
- Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer
- Open Label Arimidex in Gynecomastia
- Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
- PROACT - Pre-Operative Arimidex Compared To Tamoxifen
- Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
- Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
- Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
- Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer
- Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo
- Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer
- Anastrozole Administration in Elderly Hypogonadal Men
- Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys
- Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients
- Dose-Response of Gonadal Steroids and Bone Turnover in Older Men
- Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]
- Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
- Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer
- Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer
- Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
- Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer
- Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
- Arimidex in McCune Albright Syndrome
- Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer
- A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
- Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
Clinical trials list
click for details